Tuberculin skin test before biologic and targeted therapies : does the same rule apply for all?
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
This study aimed to compare Tuberculin Skin Test (TST) and QuantiFERON®-TB Gold In-Tube (QFT-GIT) test in rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients scheduled for biological and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) in a Bacillus Calmette-Guérin-vaccinated population. Adult RA (n = 206) and SpA (n = 392) patients from the TReasure database who had both TST and QFT-GIT prior to initiation of biological and targeted synthetic DMARDs were included in the study. Demographic and disease characteristics along with pre-biologic DMARD and steroid use were recorded. The distribution of TST and performance with respect to QFT-GIT were compared between RA and SpA groups. Pre-biologic conventional DMARD and steroid use was higher in the RA group. TST positivity rates were 44.2% in RA and 69.1% in SpA for a 5 mm cutoff (p < 0.001). Only 8.9% and 15% of the patients with RA and SpA, respectively, tested positive by QFT-GIT. The two tests poorly agreed in both groups at a TST cutoff of 5 mm and increasing the TST cutoff only slightly increased the agreement. Among age, sex, education and smoking status, pre-biologic steroid and conventional DMARD use, disease group, and QFT-GIT positivity, which were associated with a 5 mm or higher TST, only disease group (SpA) and QFT-GIT positivity remained significant in multiple logistic regression. TST positivity was more pronounced in SpA compared to that in RA and this was not explainable by pre-biologic DMARD and steroid use. The agreement of TST with QFT-GIT was poor in both groups. Using a 5 mm TST cutoff for both diseases could result in overestimating LTBI in SpA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Rheumatology international - 42(2022), 10 vom: 29. Okt., Seite 1797-1806 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
İlgen, Ufuk [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antirheumatic Agents |
|---|
| Anmerkungen: |
Date Completed 08.09.2022 Date Revised 09.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00296-022-05134-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340150254 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340150254 | ||
| 003 | DE-627 | ||
| 005 | 20231226004506.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00296-022-05134-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1133.xml |
| 035 | |a (DE-627)NLM340150254 | ||
| 035 | |a (NLM)35486197 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a İlgen, Ufuk |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tuberculin skin test before biologic and targeted therapies |b does the same rule apply for all? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2022 | ||
| 500 | |a Date Revised 09.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a This study aimed to compare Tuberculin Skin Test (TST) and QuantiFERON®-TB Gold In-Tube (QFT-GIT) test in rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients scheduled for biological and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) in a Bacillus Calmette-Guérin-vaccinated population. Adult RA (n = 206) and SpA (n = 392) patients from the TReasure database who had both TST and QFT-GIT prior to initiation of biological and targeted synthetic DMARDs were included in the study. Demographic and disease characteristics along with pre-biologic DMARD and steroid use were recorded. The distribution of TST and performance with respect to QFT-GIT were compared between RA and SpA groups. Pre-biologic conventional DMARD and steroid use was higher in the RA group. TST positivity rates were 44.2% in RA and 69.1% in SpA for a 5 mm cutoff (p < 0.001). Only 8.9% and 15% of the patients with RA and SpA, respectively, tested positive by QFT-GIT. The two tests poorly agreed in both groups at a TST cutoff of 5 mm and increasing the TST cutoff only slightly increased the agreement. Among age, sex, education and smoking status, pre-biologic steroid and conventional DMARD use, disease group, and QFT-GIT positivity, which were associated with a 5 mm or higher TST, only disease group (SpA) and QFT-GIT positivity remained significant in multiple logistic regression. TST positivity was more pronounced in SpA compared to that in RA and this was not explainable by pre-biologic DMARD and steroid use. The agreement of TST with QFT-GIT was poor in both groups. Using a 5 mm TST cutoff for both diseases could result in overestimating LTBI in SpA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Arthritis | |
| 650 | 4 | |a Interferon-gamma release tests | |
| 650 | 4 | |a Latent tuberculosis | |
| 650 | 4 | |a Spondyloarthritis | |
| 650 | 4 | |a Tuberculin test | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 700 | 1 | |a Karadağ, Ömer |e verfasserin |4 aut | |
| 700 | 1 | |a Emmungil, Hakan |e verfasserin |4 aut | |
| 700 | 1 | |a Küçükşahin, Orhan |e verfasserin |4 aut | |
| 700 | 1 | |a Koca, Süleyman Serdar |e verfasserin |4 aut | |
| 700 | 1 | |a Erden, Abdülsamet |e verfasserin |4 aut | |
| 700 | 1 | |a Bes, Cemal |e verfasserin |4 aut | |
| 700 | 1 | |a Alpay Kanıtez, Nilüfer |e verfasserin |4 aut | |
| 700 | 1 | |a Dalkılıç, Ediz |e verfasserin |4 aut | |
| 700 | 1 | |a Akar, Servet |e verfasserin |4 aut | |
| 700 | 1 | |a Mercan, Rıdvan |e verfasserin |4 aut | |
| 700 | 1 | |a Çınar, Muhammet |e verfasserin |4 aut | |
| 700 | 1 | |a Kaşifoğlu, Timuçin |e verfasserin |4 aut | |
| 700 | 1 | |a Gönüllü, Emel |e verfasserin |4 aut | |
| 700 | 1 | |a Kimyon, Gezmiş |e verfasserin |4 aut | |
| 700 | 1 | |a Ersözlü, Duygu |e verfasserin |4 aut | |
| 700 | 1 | |a Atagündüz, Pamir |e verfasserin |4 aut | |
| 700 | 1 | |a Kılıç, Levent |e verfasserin |4 aut | |
| 700 | 1 | |a Ertenli, İhsan |e verfasserin |4 aut | |
| 700 | 1 | |a Yazısız, Veli |e verfasserin |4 aut | |
| 700 | 1 | |a Ateş, Aşkın |e verfasserin |4 aut | |
| 700 | 1 | |a Kiraz, Sedat |e verfasserin |4 aut | |
| 700 | 1 | |a Kalyoncu, Umut |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d 1985 |g 42(2022), 10 vom: 29. Okt., Seite 1797-1806 |w (DE-627)NLM012644315 |x 1437-160X |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:10 |g day:29 |g month:10 |g pages:1797-1806 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00296-022-05134-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 10 |b 29 |c 10 |h 1797-1806 | ||